privat isra pharmaceut compani focus develop
complex activ pharmaceut ingredi drug reformul life-cycl manag
product compani lead product glatiram acet depot ga depot
once-monthli inject glatiram acet treatment multipl sclerosi
product reformul teva glatiram acet drug copaxon requir either
daili thrice weekli inject expect launch phase pivot trial
evalu ga depot also broad portfolio reformul
life-cycl manag product focus blockbust drug diseas
neuropath pain epilepsi schizophrenia built api manufactur facil
order fulli control suppli chain
point discuss
reformul known molecul glatiram acet mapi lead life-cycl manag product glatiram acet depot
ga depot make use api teva nyse teva copaxon treatment relaps form multipl sclerosi
copaxon requir daili thrice-weekli subcutan self-administ inject ga depot requir monthli intraven
inject administ healthcar profession patient home long-act formul provid better efficaci
expect improv complianc current treatment complianc rate low among ms patient studi report
rang nonadher defin take less requir medic rate expect
launch phase trial year evalu safeti efficaci ga depot could support regulatori file via
pathway addit ga depot develop gener form glatiram acet plan submit
anda product fda
larg market opportun treatment improv conveni administr teva copaxon gener
billion sale overal market ms drug estim exceed billion mapi ga depot long-act
formul copaxon improv efficaci ga depot well-posit captur substanti portion copaxon sale
follow teva introduct thrice-weekli mg copaxon dose daili mg ga-treat patient convert
mg option within approxim two year treatment cure diseas ms patient frequent chang therapi base
sole conveni administr safeti concern teva high convers rate drug similar efficaci increas
conveni administr suggest like abl convert larg portion copaxone-tr patient
conveni effect ga depot drug survey data mapi pharma phase ii studi provid evid
patient would strongli prefer monthli daili treatment survey copaxone-tr patient report
will switch ga depot treatment
complic broad suppress immun system exist ms therapi mani newer ms therapi
modul immun system broad effect lymphocyt although newer drug gener lot optim
potenti improv patient outcom ms safeti concern associ immunomodulatori drug make
prescript monitor use cumbersom induc alter immun system may predispos ms patient
opportunist community-acquir infect alter vaccin respons malign autoimmun diseas rare case
use tysabri natalizumab novarti nyse nv gilenya fingolimod tecfidera
associ develop progress multifoc leukoencephalopathi pml rare demyelin disord
compar ga robust safeti profil sinc fda approv ga product use treat ms patient without
sever advers effect report death associ treatment
analyst certif disclosur pleas see page
life-cycl manag product address lyrica risperd market also develop extend releas
formul pregabalin api nyse lyrica lyrica widely-prescrib drug treatment neuropath
pain fibromyalgia epilepsi lyrica gener approxim billion world-wide revenu us annual cost
pain includ direct medic healthcar cost indirect cost societi estim billion lyrica
go off-pat allow entri gener market given expect improv conveni profil
mapi pregabalin formul could captur substanti share patient popul current treat lyrica
develop form lyrica partnership jiangsu nhwa pharmacuet co recent complet success
pharmacokinet studi extended-releas formul drug compani plan pursu regulatori pathway
use lyrica refer drug
also develop once-monthli formul risperidon lai long-act inject lai formul
second-gener atyp antipsychot risperidon treatment schizophrenia risperidon activ ingredi johnson
 johnson risperd approv fda johnson johnson later develop version risperd requir
twice-monthli dose oppos daili dose second version drug risperd consta approv fda
despit improv dose conveni complianc treatment schizophrenia remain low recent studi found
individu schizophrenia respond medic adher treatment mapi risperidon lai improv
upon risperid consta once-monthli dose could improv patient complianc current plan
bioequival trial risperidon lai support regulatori pathway use risperd consta refer drug
wide portfolio reformul product gener addit ga depot pregabalin er risperidon lai
develop number drug regulatori pathway mapi develop buspiron er
extend releas formul buspar buspar daily-administ oral antipsychot treatment anxieti gener
approxim million sale mapi also develop long-act inject formul paliperidon palmit
activ ingredi invega sustenna invega trinza invega sustenna invega trinza use treatment schizophrenia mania
bipolar disord two drug gener billion revenu also develop gener version
darunavir fingolimod glatiram acet risperidon paliperidon palmit seek approv product
anda regulatori pathway due gap fingolimod patent coverag mapi gener fingolimod product alreadi receiv
approv isra ministri
kol insight critic advantag provid glatiram acet recent attend kol event dr carlo tornator
professor chairman neurolog georgetown univers medic center well director multipl sclerosi patient
cover special practic medstar georgetown univers hospit washington dc dr tornator comment current
treatment landscap ms patient number safeti concern associ mani avail treatment
seriou side effect associ treatment tysabri greater risk progress multifoc leukoencephalopathi gilenya
greater risk develop seriou infect physician patient perspect glatiram acet attract
treatment option given strong efficaci impress safeti profil monthli inject ga depot combin
deliveri inject healthcar profession like translat greatli improv complianc
launch phase trial ga depot relaps form ms
file fdf registr gener darunavir
submiss anda gener ga mg dosag
tabl content
glatiram acet depot life-cycle manag version copaxon
mechan action
caus pathogenesi
diagnosi symptom
price market share analysi
competit landscap ms treatment
ms drug develop
pregabalin er extended-releas formul lyrica
mechan action
caus pathogenesi
symptom diagnosi
price market share analysi
competit landscap neuropath pain treatment
drug develop np
risperidon lai once-monthli formul risperd consta
mechan action
caus pathogenesi
symptom diagnosi
competit landscap schizophrenia treatment
risk invest
isra clinical-stag compani focus develop life cycl manag product base
long-act depot inject slow releas formul well gener drug base activ pharmaceut
ingredi api widely-us brand drug thu compani intend capit long track record
safeti efficaci blockbust drug develop successor product compani lead product glatiram
acet depot ga depot once-monthli dose formul teva nyse teva copaxon
treatment relaps form multipl sclerosi rm teva copaxon current widely-prescrib ms
drug gener billion sale howev gener entri put increas pressur teva copaxon
despit wide prescrib complianc treatment low make difficult patient see clinic
improv take drug treatment either administ patient daili thrice-weekli
self-administ subcutan inject compar mapi pharma ga depot once-monthli nurse-
administ intraven inject increas conveni administr expect improv treatment
complianc greater plan initi phase studi rm patient support regulatori
file via regulatori pathway result studi expect
addit ga depot mapi develop reformul nyse lyrica pregabalin johnson
johnson nyse risperd consta risperidon bristol-my squibb nyse bm buspar buspiron
brand drug product histor success gener signific revenu mapi also
develop gener drug product anda regulatori pathway includ gilenya fingolimod prevista
darunavir copaxon glatiram acet risperd risperidon invega sustenna paliperidon palmit mapi
gener fingolimod product receiv approv isra ministri compani
look market partner product figur show mapi full product pipelin mapi built in-
hous plant api manufactur becom fully-integr compani full control suppli chain
mapi pharmaceut develop plan commerci life-cycl manag lcm product finish
dosag formul fdf complex activ pharmaceut ingredi api mapi own api plant
israel lead industri chemic park neot hovav facil allow full control mapi product
api drug product addit facil allow reduc tax rate compar typic
corpor tax rate mapi also develop number product chines compani
commerci chines market data trial perform china use develop
product market
depot technolog mapi leverag depot technolog develop long-act inject product within
depot product micron-larg microspher encapsul api without modifi chemic properti
molecul microspher made poli lactide-co-glycolid plga bio-degrad polyest
use number fda-approv drug depot drug design releas drug pre-specifi extend
period time depot product also make use mapi proprietari particl size reduct technolog allow
reformul product inject
life-cycle manag product mapi strategi develop lcm product identifi commerci
success brand drug re-develop ad valu driver provid critic advantag
market leader exampl mapi lead product glatiram acet ga depot once-monthli inject
treatment relapsing-remit multipl sclerosi ga depot life-cycl manag version teva nyse
teva copaxon product requir daili thrice-weekli dose gener billion sale
ga depot may provid patient conveni treatment option mapi may posit captur
signific portion teva market share thu teva may particularli interest incentiv enter
licens discuss mapi order preserv revenu stream copaxon mapi also develop lcm
version nyse lyrica johnson johnson nyse risperd consta two blockbust
drug mapi seek approv product regulatori pathway
complex activ pharmaceut ingredi finish dosag formul addit compani
lcm platform mapi also develop complex api fdf develop manufactur sale
gener pharmaceut product use proprietari know-how technolog mapi capabl develop
product avoid product process patent limit mapi focus develop api consid
difficult manufactur therefor higher barrier entri market may decreas number
compet gener product market prevent price eros typic present gener
enter market specif mapi develop gener version drug schedul go off-pat
compani lead gener product includ gener glatiram acet risperidon fingolimod
darunavir compani also maintain strong patent portfolio patent famili surround
complex api formul
glatiram acet depot life-cycle manag version copaxon
glatiram acet ga depot life-cycl manag version teva nyse teva copaxon glatiram
acet wide use treatment relaps form multipl sclerosi rm gener billion
sale sandoz subsidiari novarti nyse nv momenta launch
glatopa first gener version copaxon dose mg/ml deliv daili late
launch anoth gener version copaxon glatiram acet inject gener product
avail mg/ml mg/ml dose februari sandoz momenta receiv fda
approv glatopa dose mg/ml entri product market expect heavili increas
price pressur copaxon could bring teva tabl partnership discuss
multipl sclerosi ms highly-debilit progress diseas affect estim million individu
world-wide peopl ms relapsing-remit form diseas patient experi new
symptom diseas worsen follow period diseas remiss last month year
progress form diseas patient experienc continu steadi worsen symptom time
period remiss worsen symptom typic involv impair mobil gait greatli
impact patient independ qualiti life
strong safeti profil copaxon consid one primari first-lin treatment relapsing-
remit ms copaxon avail mg daili mg thrice-weekli form patient requir self-
administ drug subcutan inject burden associ frequenc
treatment self-administ inject complianc copaxon low studi report rang
nonadher defin take less requir medic rate
reformul glatiram acet long-act depot formul allow once-monthli
dose reformul expect increas conveni treatment improv complianc
consequ maxim benefit patient receiv treatment plan run phase trial
evalu safeti efficaci ga depot compani complet phase ii trial show ga
depot strong efficaci safeti profil studi show ga depot strong efficaci data
studi also suggest ga depot may provid even greater therapeut effect copaxon
administ everi four week instead daili thrice weekli
addit monthli dose ga depot would deliv inject healthcar profession
patient home self-inject consid major barrier treatment complianc mani patient
unwil perform task featur ga depot expect improv conveni treatment
thusli drive complianc close greater complianc treatment would meaning improv
patient qualiti life
compani plan pursu fda approv via pathway use copaxon refer drug
addit ga depot develop gener form glatiram acet plan submit anda
product fda manufactur plant neot hovav israel
compani manufactur ga api
mechan action ga depot long-act inject ga releas within day within
depot product micron-larg microspher encapsul ga without modifi chemic properti
molecul microspher made poli lactide-co-glycolid plga bio-degrad polyest
use number fda-approv
glatiram acet ga synthet amino acid copolym compos l-alanin l-lysin l-glutam acid
l-tyrosin ratio molecul design resembl mimic encephalitogen
properti myelin basic protein mbp believ one critic myelin autoantigen involv
pathogenesi ms murin model diseas experiment autoimmun enceph eae process
discoveri ga first design induc eae mice similar mbp howev instead
induc eae copolym protect eae led develop molecul therapeut
addit abil ga eas diseas symptom eae induc encephalitogen
besid mbp protelipid protein plp myelin oligodendrocyt glycoprotein mog suggest ga
suppress abil limit mbp
ga first therapeut agent make use copolym activ ingredi complex
amino acid mixtur ga lack specif activ compon mechan action poorli
understood research recent howev number research studi provid evid hypothes
mechan action
ga first bind major histocompat mhc class ii molecul bind mhc class ii molecul occur
rapidli ga even outcompet molecul bind outcompet molecul ga inhibit
antigen act induc respect pathogen addit mhc bind ga act
t-cell receptor antagonist inhibit immun respons epitop mbp peptid howev ga
bind abil may respons clinic effect ga ga broken peripheri
move relev activ demyelin neuron rather like
immunotherapi neurotroph factor instead mediat ga modulatori effect within
adapt immun system effect primari mechan action ga believ aris abil
modifi t-cell respons pro-inflammatori anti-inflammatori anim research shown ga
treatment act t-cell peripheri turn lead cytokin releas wildtyp t-cell-
defici rat underw damag sciatic nerv ga treatment abl induc recoveri damag nerv
wildtyp suggest glatiram acet act nervou system least partial t-
cell ga-activ t-helper th cell subtyp secret anti-inflammatori cytokin interleukin
transform growth factor tgf -b rather pro-inflammatori cytokin
arnon aharoni mechan action glatiram acet multipl sclerosi potenti
develop new applic pna
weber hohlfeld zamvil mechan action glatiram acet treatment multipl sclerosi
aharoni mechan action glatiram acet multipl sclerosi beyond autoimmun review
aharoni mechan action glatiram acet multipl sclerosi beyond autoimmun review
arnon aharoni mechan action glatiram acet multipl sclerosi potenti
develop new applic pna
luria et al glatiram acet immun system augment peripher nerv regener rat crush sciatic
nerv model journal bone joint surgeri
aharoni et al glatiram acetate-specif cell brain express helper cytokin brain-deriv
neurotroph factor vivo
recent research suggest ga treatment also effect ga-react t-cell untreat ms
patient t-cell impair regulatori follow sever month ga treatment ms patient
experienc recoveri cell regulatori activ level level similar healthi individu
associ clinic improv diseas symptom ga-react t-cell believ bring
clinic improv symptom suppress pro-inflammatori cell activ similar activ
ga may also interact b-cell induc develop ga-specif antibodi isotyp
isotyp reflect shift pro-inflammatori anti-inflammatori respons shift like
accompani product anti-inflammatori cytokin figur provid overview
differ mechan action ga immunomodulatori effect ga-react t-cell b-cell
figur immunomodulatori mechan action ga peripheri
nativ immun system effect number studi shown ga bring chang antigen
present cell apc apc induc protect anti-inflammatori key apc interest
ms pathogenesi monocyt dendrit cell follow ga treatment monocyt exhibit lower level
tnf inflammatori cytokin compar baselin ga-treat ms patient dendrit
cell also exhibit decreas level tnf-a increas level cytokin
compar untreat ms patient importantli ga-treat dendrit cell abl promot
aharoni mechan action glatiram acet multipl sclerosi beyond autoimmun review
aharoni mechan action glatiram acet multipl sclerosi beyond autoimmun review
weber hohlfeld zamvil mechan action glatiram acet treatment multipl sclerosi
differenti naiv t-cell affect overal t-cell growth increas cell differenti suggest
switch anti-inflammatori respons follow ga treatment evid apc influenc
differenti t-cell recent research also support effect ga-react cell type ii monocyt
posit feedback mechan work requir better understand precis effect ga treatment
apc t-cell relationship
neuroprotect effect recent research also suggest ga may mediat neuroprotect effect one
vitro studi found ga treatment led product neurotroph factor ga-react specif
ga-react t-cell gener brain-deriv neurotroph factor bdnf critic factor
differenti growth neuron mainten glial cell function neurotroph factor seem
respond ga treatment includ neurotrophin insulin-lik growth factor
typic level neurotroph factor tend reduc ms patient howev ga-treat patient show
normal neurotroph factor level suggest ga may neuroprotect effect though effect
within myelin-form oligodendrocyt depend precursor order respond
oligodendrocyt precursor oligodendrocyt progenitor cell opc must go prolifer migrat
differenti becom oligodendrocyt research ga-treat eae mice research found ga
abl enhanc myelin repair process research believ ga function amplifi prolifer
surviv opc subsequ recruit opc injuri site ga may also bring effect
differenti opc oligodendrocyt induc transform earli form opc
pre-clin data test safeti efficaci research test long-act ga depot vitro
vivo model vitro releas profil determin calcul concentr ga sampl
time use gel-perm chromatographi shown figur drug releas within day
gradual releas provid support use ga depot once-monthli administr
weber hohlfeld zamvil mechan action glatiram acet treatment multipl sclerosi
aharoni mechan action glatiram acet multipl sclerosi beyond autoimmun review
aharoni mechan action glatiram acet multipl sclerosi beyond autoimmun review
experiment autoimmun encephalomyel eae murin model ms character primari
demyelin axon central nervou system eventu result hind-limb paralysi eae
t-cell-medi autoimmun diseas diseas induc subcutan inject emulsifi myelin
oligodendrocyt glycoprotein mog back mous subsequ inject bordetella pertussi
toxin pbv hour later sever eae assess clinic score system shown figur
figur clinic score eae
normal mous overt sign diseas
hind limb front limb paralysi
complet paralysi sacrific human reason
moribund state death eae
anim studi efficaci ga depot treat eae clinic score eae bodi weight assess
daili day follow immun mice random receiv mg im ga depot mg im ga
depot mg/day sc copaxon salin sc ga depot deliv via one singl inject day treatment
copaxon deliv via daili inject first day treatment mean diseas durat mg
depot group day compar day copaxon treatment group day control group
mean diseas durat differ significantli ga depot control treatment group notabl
signific differ mean diseas durat copaxon control treatment group shown
figur cours treatment mg im ga depot-tr mice experienc slower worsen
symptom assess mean clinic score importantli singl inject ga depot abl bring
compar effect nine inject copaxon
figur mean clinic score eae mice follow treatment
note arrow indic time point drug inject
figur show bodi weight exhibit similar trend mean clinic score
mg ga depot-tr mice experienc significantli higher bodi weight cours treatment
higher bodi weight indic clinic improv symptom result provid support efficaci ga
figur bodi weight eae mice ga depot copaxon control treatment
note arrow indic time point drug inject
safeti profil sinc drug fda approv ga use treat ms patient without seriou
advers effect associ year sinc drug approv million
patient-year exposur drug underscor well-studi safeti profil common
boster efficaci safeti cost-effect glatiram acet treatment relapsing-remit multipl
ziemssen et al long-term safeti toler glatiram acet mg/ml treatment relaps form
multipl sclerosi expert opinion drug safeti
side effect ga treatment local inject site reaction occur roughli patient
report death associ ga
compar disease-modifi treatment ms ga strong safeti toler interferon-
base drug may caus impair liver function leukopenia thyroid diseas class drug also
associ increas risk spastic depress fatigu none advers effect report
ga-treat ms patient interferon antibody-bas drug ms patient may develop neutral
antibodi associ treatment occur ga treatment ga
mechan action involv immunosuppress
mapi phase ii trial test safeti efficaci ga depot treatment gener safe well-toler
major advers event mild relat inject site reaction isr isr last briefli
common isr includ pain indur swell erythema fewer isr mg group
compar mg group suggest superior safeti toler mg ga depot dose patient
experienc safeti issu switch copaxon ga depot drug
multipl sclerosi ms autoimmun diseas central nervou system affect brain spinal
cord optic nerv etiolog diseas current unknown research postul trigger
one environment factor genet suscept individu ms immun system select target
myelin sheath surround nerv fiber caus scar also known sclerosi damag fiber
seen develop lesion within white matter brain
figur illustr normal myelin sheath surround nerv fiber axon top panel versu exposur
fiber myelin damag damag larg collect axon brain creat distinct ms lesion
damag sheath caus improp alter impuls propag result rang symptom includ
blur loss vision numb limb lack coordin balanc weak cognit issu
mri imag gadolinium stain help visual lesion import part diagnost process
addit t-lymphocyt appear involv directli attack myelin inflammatori respons
also act hasten breakdown process recruit immun cell factor
ford et al continu long-term immunomodulatori therapi relaps multipl sclerosi result
year analysi us prospect open-label studi glatiram acet mult scler
boster efficaci safeti cost-effect glatiram acet treatment relapsing-remit multipl
karussi et al long-term treatment multipl sclerosi glatiram acet natur histori subtyp
anti-glatiram acet antibodi correl clinic efficaci neuroimmunol
type ms nation multipl sclerosi societi publish result intern survey
clinician treat patient data survey show diagnost consensu exist
ms field led descript four type ms progressive-relaps secondary-progress
primary-progress relapsing-remit ms figur provid explan type ms
percentag patient diagnos type relapsing-remit rrm common form
ms ms may categor activ activ indic whether patient current
figur type multipl sclerosi
patient diagnosi
rrm patient
steadi worsen diseas start
steadi worsen without sign relaps
relaps follow partial complet
worsen steadili without relaps
approxim ms patient initi diagnos relapsing-remit ms rrm
approxim patient diagnos rrm develop secondari progress spm within year
caus pathogenesi ms chronic autoimmun diseas result episod immune-
mediat attack myelin throughout caus ms well understood diseas progress
highli variabl among affect individu patient ms character altern period clinic
lublin et al defin clinic cours multipl sclerosi neurolog
worsen follow abat symptom diseas state known relapsing-remit ms rrm
pathogenesi ms thought involv rang genet environment lifestyl dietari factor
type ms character inflammatori demyelin lesion consist lymphocyt
infiltr cross blood-brain barrier relapsing-remit progress form ms activ tissu
damag link activ microglia loss myelin oligodendrocyt compromis
import neuron support function brain eventu lead neurodegener long term
format glial scar failur remyelin keep pace demyelin result perman tissu
injuri contribut acceler diseas process progress form
cell ms overal number cell differ healthi affect individu cell
ms patient exhibit differ featur associ cell-induc myelin-react cell healthi
individu tend exhibit nave phenotyp cell ms patient exhibit activ memori
phenotyp activ phenotyp myelin-react cell associ increas inflammatori respons
base subsequ secret pro-inflammatori cytokin express chemokin receptor
inflammatori respons produc myelin-specif cell depend type cytokin produc
type helper cell produc high amount interferon-g lymphotoxin low amount
believ research strongli involv inflammatori respons associ ms
meanwhil type helper cell known induc anti-inflammatori respons produc high
amount ms patient tend express cytokin product consist
respons healthi individu tend express cytokin consist
respons cytokin certain interferon interferon-b caus increas cell
differenti cell type anim studi confirm role
b-cell ms b-cell also shown play critic role express increas b-cell
prolifer cerebrospin fluid mutat b-cell receptor ms patient suggest b-cell
respond specif antigen on-going research focus determin target autoreact
b-cell
regulatori cell ms regulatori cell treg cell also believ
relev ms diseas regulatori cell shown critic suppress
autoimmun diseas reduc level impair function regulatori cell individu may
develop autoimmun diseas support anim studi mutat cell lead
prinea jw et al immunopatholog secondary-progress multipl sclerosi annal neurolog
lassmann et al architectur inflammatori demyelin lesion implic studi pathogenesi
neuropatholog appli neurobiolog
frohman rack rain multipl sclerosi plaqu pathogenesi new england journal
frohman rack rain multipl sclerosi plaqu pathogenesi new england journal
fraussen cell character reactiv analysi multipl sclerosi autoimmun review
frohman rack rain multipl sclerosi plaqu pathogenesi new england journal
spontan develop autoimmun diseas compar healthi individu ms patient show
significantli reduc function regulatori cell
diagnosi symptom multipl sclerosi diagnos use varieti clinic measur includ medic
histori neurolog exam magnet reson imag mri brain evok potenti test analysi
cerebrospin fluid ms diagnosi publish criteria provid guidelin regard
combin clinic metric indic clearest measur ms relaps attack last
least hour absenc fever infect lesion brain presenc two attack
two lesion suffici make posit diagnosi patient fewer relaps fewer lesion requir
addit test confirm ms figur show exampl brain lesion patient ms top panel show
mri imag patient primari progress ms arrow point brain lesion area
inflamm myelin destruct bottom panel enlarg imag two lesion
treatment cur therapi avail ms exist treatment rrm focu decreas
frequenc flare-up shorten durat allevi symptom diseas order improv
patient qualiti life one drug approv primari progress ms ppm one approv secondari
progress ms spm drug recent approv ppm ocrevu target antigen cell
drug approv spm mitoxantron although rare use due potenti cardiac toxic
viglietta loss function suppress regulatori cell patient multipl sclerosi journal
experiment medicin
 et al recommend diagnost criteria multipl sclerosi guidelin
diagnosi multipl sclerosi annal neurolog
van der kolk et al clinic applic mri brain european journal radiolog
risk induc secondari leukemia figur highlight main disease-modifi treatment approv rrm
patient worth note exact mechan action fulli understood mani agent
howev drug work dampen immun respons rather prevent initi immun activ
addit safeti concern mani treatment relat broad suppress host
immun predispos patient opportunist infect autoimmun disord complic
rare case use tysabri gilenya tecfidera associ develop progress multifoc
inhibitor dna synthesi
glatiram acet teva nyse teva copaxon novartis/sandoz nyse nv glatopa
glatiram acet inject mechan action ga teva copaxon
novartis/sandoz glatopa mylan glatiram acet inject ga mapi pharma
reformul drug numer studi provid evid efficaci safeti ga treatment
ms us glatiram acet studi greater patient treat glatiram acet
still walk without assist individu exhibit reduct annual relaps rate baselin
langer-gould et al progress multifoc leukoencephalopathi patient treat natalizumab new england
journal medicin
per addit mri studi shown glatiram acet reduc inflammatori activ
bayn de betaseron novarti nyse nv extavia plegridi beta
interferon naturally-occur cytokin human modul immun activ shown reduc
relaps rate one-third beta interferon often use rrm patient toler glatiram acet
use interferon beta lead flu-lik symptom patient receiv interferon beta caus liver
function abnorm leukopenia thyroid
tysabri natalizumab tysabri monoclon antibodi subunit certain
integrin protein express surfac leukocyt protein critic leukocyt adhes
endotheli cell critic infiltr inflammatori cell tissu safeti concern
associ use drug sinc broad immunosuppress effect put patient risk
gilenya fingolimod novarti nyse nv gilenya first oral administ drug approv treat
rrm drug receptor modul thought impact lymphocyt
infiltr phase program gilenya found superior beta interferon reduc
annual relaps rate
aubagio teriflunomid sanofi nyse sni aubagio oral agent inhibit synthesi pyrimidin
rapidli prolifer cell reduc prolifer lymphocyt aubagio abl
reduc extent lymphocyt infiltr consequ sever inflammatori
tecfidera dimethyl fumar tecfidera oral immunomodulatori agent lead
activ nuclear factor erythroid deriv key regul cellular machineri
ford cc et al continu long-term immunomodulatori therapi relaps multipl sclerosi result
year analysi prospect open-label studi glatiram acet multipl sclerosi
comi et al european/canadian multicent double-blind random placebo-control studi effect
glatiram acet magnet reson imag measur diseas activ burden patient relaps multipl
sclerosi annal neurolog
hauser sl goodwin ds multipl sclerosi demyelin diseas fauci braunwald kasper
dl hauser sl ed harrison principl intern medicin volume ii ed new york mcgraw-hil medic
multipl sclerosi brust jcm ed current diagnosi treatment neurolog new york lang medic
chun hartung mechan action oral fingolimod multipl sclerosi clinic
cohen ja al oral fingolimod intramuscular interferon relaps multipl sclerosi new england journal
kappo et al placebo-control trial oral fingolimod relaps multipl sclerosi new england journal
calabresi pa et al safeti efficaci fingolimod patient relapsing-remit multipl sclerosi
oh oconn pw teriflunomid treatment multipl sclerosi current evid futur prospect
therapeut advanc neurolog disord
prevent oxid drug also anti-inflammatori effect promot immun
respons defin phase studi tecfidera found superior beta interferon reduct
annual relaps rate drug also favor safeti profil rel
lemtrada alemtuzumab sanofi nyse sni lemtrada monoclon antibodi surfac
protein express surfac matur lymphocyt progenitor cell bind antibodi
lymphocyt target cell destruct reduc pool infiltr lymphocyt site ms lesion
drug approv treat chronic lymphocyt leukemia cll cutan t-cell lymphoma ctcl
t-cell lymphoma recent approv treatment rrm howev lemtrada associ
opportunist infect result broad immun suppress increas rate autoimmun condit
weight physician patient consid
zinbryta daclizumab zinbryta once-monthli monoclon antibodi
surfac protein recent approv fda drug infus per month thought
modul mediat activ immun cell
ocrevu ocrelizumab roch vtx ocrevu monoclon antibodi antigen
normal malign cell bind antigen antibodi recruit bodi natur immun
system respons attack kill target cell healthi cell regener follow treatment
stem cell cell progenitor express antigen therefor target
antibodi drug administ intraven infus deliv everi six month safeti
concern associ drug patient may develop seriou infect increas risk cancer
epidemiolog epidemiolog ms complex famili histori effect risk develop
ms rel ms patient higher rate develop women like
ms men affect individu diagnos third fourth decad life median
age diseas onset roughli year age age ratio femal diseas
research suggest preval increas individu equat although notion
preval vari wide make hard estim accur number ms patient
world-wide howev combin better diagnost techniqu prolong surviv led increas
preval ms common autoimmun diseas affect roughli million
bomprezzi dimethyl fumar treatment relapsingremit multipl sclerosi overview therapeut
advanc neurolog disord
gold et al placebo-control phase studi oral relaps multipl sclerosi new england journal
sheremata et al dimethyl fumar treat relaps multipl sclerosi expert opinion drug safeti
hartung et al alemtuzumab new therapi activ relapsingremit multipl sclerosi multipl sclerosi
weinshenk epidemiolog multipl sclerosi neurolog clinic
wingerchuck multipl sclerosi current emerg disease-modifi therapi treatment
kock-henriksen srensen chang demograph pattern multipl sclerosi epidemiolog
diagnos individu accord cleveland clinic roughli ms patient us
estim ms patient europ well estim averag annual cost associ ms
treatment per diagnos individu
market size figur display breakdown market ms drug teva nyse teva copaxon glatiram
acet remain market leader sale roughli billion howev copaxon sale expect
declin due expir patent entri gener market sandoz subsidiari novarti nyse
nv momenta launch glatopa gener copaxon dose mg
product gener million sale octob receiv fda approv
ga gener product dose mg/ml mg/ml februari sandoz momenta also receiv
fda approv glatopa higher dose mg/ml addit ga gener expect enter market
tecfidera dimethyl fumar lead among oral brand ms drug billion
sale seven ms drug exceed billion sale within total market worth billion
ceil market share exist ms therapi appear roughli oral drug interferon-bas
drug togeth occupi major share market howev type treatment associ seriou
safeti issu oral drug sale plateau result safeti issu incid includ malign fatal
infect longer prescrib first-lin interferon-bas drug sale declin due
drug low efficaci caus flu-lik symptom patient sale interferon-bas drug total roughli
billion project declin billion
figur market share brand ms drug
goldmann prinz role microglia autoimmun clinic development immunolog
kobelt et al cost qualiti life patient multipl sclerosi europ neurol neurosurgeri psychiatri
sorensen balanc benefit risk disease-modifi therapi patient multipl sclerosi journal
neurolog scienc
ga depot ultim success trial approv ms ga depot may offer conveni
effect form copaxon patient captur signific market share teva copaxon ga depot could
becom first-lin therapi and/or long-term mainten treatment rrm
price market share analysi wholesal acquisit cost wac approv ms drug rang
recent entrant market command premium price shown figur
posit ga depot treatment could take copaxon market share confirm
safe efficaci phase ga depot strong posit market success could creat strong
financi incent teva licens product order preserv revenu stream gener
ga product avail glatopa glatiram acet inject ga depot offer clear advantag gener
would therefor like price premium
figur annual cost ms drug
note first treatment cours second treatment cours month later report price depend dose
possibl ga depot use combin approv ms drug mean
would necessarili take market share competitor order grow sale glatiram acet product
often consid strong candid combin therapi strong safeti profil absenc
mapi evalu product ga depot treatment relaps form ms rm primari progress
ms ppm mapi complet phase ii studi israel evalu ga depot treatment rm patient
studi show ga depot strong efficaci data suggest ga depot may even provid greater
therapeut effect copaxon administ month instead daili thrice weekli base
posit result trial mapi initi phase trial rm patient result phase
trial posit mapi plan file regulatori approv ga depot regulatori pathway
recent mapi initi prospect open-label phase iia trial primari progress ms patient
phase ii trial test safeti efficaci ga depot treatment
complet phase ii trial israel test safeti toler efficaci once-monthli ga
depot inject relapsing-remit ms rrm patient trial confirm efficaci low high
dose drug provid support safeti toler dose drug advers event
mainli relat injection-sit reaction
trial design prospect open-label multicent phase ii trial measur safeti toler efficaci
long-act intramuscular ga formul deliv month rrm patient patient
treat copaxon least month prior studi enrol core studi last one year patient
given option continu treatment follow end core studi patient either given mg
mg dose drug patient mg dose group mean ms durat year patient
mg dose group mean ms durat year
primari endpoint includ measur advers event laboratori data physic examin local skin
reaction inject site withdraw rate secondari endpoint includ relaps rate treatment compar
rate treatment copaxon chang brain lesion baselin measur mri scan score
expand disabl statu scale edss compar baselin research also evalu percent
patient achiev evid diseas activ neda neda defin relaps
confirm disabl progress new lesion new gadolinium-enhanc lesion
trial result overal mg mg-treat group show clinic benefit cours treatment
within per protocol pp popul patient exhibit new lesion newli enhanc lesion
mri scan compar baselin patient within pp popul achiev neda asid
one case princip investig decid defer inject treatment complianc
safeti major advers event mild relat inject site reaction isr isr last
briefli common isr includ pain indur swell erythema fewer isr mg group
compar mg group suggest superior safeti toler mg ga depot dose patient
experienc safeti issu switch copaxon ga depot drug
phase trial test efficaci safeti toler ga depot treatment
design phase trial base success plegridi teva success copaxon phase
pivot trial compani receiv fda ema approv respect trial patient
enrol trial begin
trial design multicent random double-blind placebo-control phase trial aim measur
safeti toler efficaci long-act intramuscular inject ga depot rm patient activ
treatment patient receiv ga depot dose mg control group patient receiv placebo treatment
last one year patient given option continu treatment ga depot follow end
treatment studi phase primari endpoint efficaci measur annual relaps rate
secondari endpoint includ chang brain lesion measur mri scan measur safeti
phase ii trial test safeti efficaci ga depot primari ms
mapi recent initi phase iia trial israel assess ga depot treatment primari progress ms
glatiram acet prevent worsen disabl may provid benefit patient activ
trial design prospect open-label studi aim assess safeti efficaci ga depot delay
accumul disabl primari progress ms ppm patient enrol patient receiv
mg intramuscular inject ga depot inject deliv everi four week total week
primari endpoint studi assess advers event inject site reaction secondari endpoint
includ confirm diseas progress whole brain volum chang cortic volum chang top-line result
studi expect late
competit landscap ms treatment
convers copaxone-tr patient follow teva introduct thrice-weekli mg dosag
copaxon daili mg ga-treat patient convert mg option within approxim two
treatment cure diseas ms patient frequent chang therapi base sole conveni
administr safeti concern teva high convers rate drug similar efficaci increas
conveni administr suggest like abl convert larg portion copaxone-
treat patient conveni ga depot drug addit teva earn indic mg
thrice-weekli copaxon product account copaxon prescript underscor strong
patient prefer conveni dose survey data mapi pharma phase ii studi provid
evid patient would strongli prefer monthli daili treatment survey copaxone-tr
patient report will switch ga depot treatment even though treatment associ
slightli increas rate inject site advers event
chang treatment landscap due safeti issu seriou advers event associ
oral interferon-bas ms drug diseas treatment landscap shift away form treatment
oral drug sale plateau interferon-bas drug sale declin shift provid space ga depot
enter market copaxon one wide use first-lin treatment rrm ga depot
improv version copaxon well-posit captur substanti share ms treatment
market copaxon avail year widely-prescrib establish market
place drug may facilit adopt ga depot approv
increas treatment complianc ga depot ga depot would administ patient monthli
nurs patient home increas conveni administr decreas treatment burden like
attract ms patient current treatment complianc rate low among ms patient studi
report rang nonadher defin take less requir medic rate
part due fact improv symptom may evid ms patient sinc
slow patient relaps rate may difficult appreci one day day life patient
experi immedi improv treatment frequent self-administ inject home
may inclin skip treatment ga depot treatment predict maxim patient complianc greater
mapi pharma phase ii trial studi efficaci safeti ga depot treatment complianc
earli evid ga depot superior efficaci copaxon mapi open-label phase ii trial rrm
patient treat ga depot dose mg mg year end year achiev
state evid diseas activ neda neda defin absenc new enhanc lesion
mri scan lack score progress edss absenc relaps consid impress
standard meet diseas popul gener experi continu worsen symptom time
meanwhil efficaci data placebo-control studi evalu copaxon rrm patient show
annual relaps rate copaxone-tr patient compar placebo-tr
group copaxone-tr patient clearli signific benefit placebo-tr patient
still remain sizabl meanwhil open-label phase ii trial one patient experienc relaps
one-year treatment period note relaps accompani worsen edss score
efficaci data mapi phase trial need directli compar ga depot copaxon data
present thu far provid evid greater therapeut benefit associ ga depot
drug price follow entri gener market follow expir copaxon patent
number compani began develop gener version ga compani includ synthon
dr reddi momenta sandoz subsidiari novarti nyse nv momenta nasdaq
receiv fda approv gener ga glatopa dosag mg/ml octob receiv fda
approv gener ga inject dosag mg/ml mg/ml februari sandoz
momenta also receiv fda approv glatopa dose mg/ml teva alreadi seen declin copaxone-
sale sinc entri glatopa onto market compet product like continu drive
annual price ga-bas drug reduc market share depot technolog mapi ga formul
allow drug price premium compar gener howev increas competit like
klauer complianc adher treatment multipl sclerosi neurol
chain-enhanc activ
ms drug develop
larg major drug develop aim slow diseas progress target inflammatori aspect
drug wide rang target includ antigen receptor
surfac antigen oligodendrogli cell protein figur provid overview drug
develop relaps ms
figur drug develop relaps ms
cluster differenti antigen express sole lymphocyt pre-b
cell plasmacytoid immunoblast stage differenti research suggest treatment
antibodi target b-cell lead reduct lesion ms patient declin relaps rate current
approv ocrevu drug target use treatment rrm progress ms drug
target receptor arzerra ofatumumab ublituximab
cross naismith establish novel disease-modifi treatment multipl sclerosi journal intern
receptor g-protein coupl receptor affin lysophospholipid
lipid secondari messeng express lymphocyt
believ play key role egress lymphocyt form drug target receptor
treatment ms either specif target and/or receptor subtyp drug bind
lead inhibit certain lymphocyt migrat inflamm site therefor lead
decreas inflammatori activ drug bind lead activ certain cell allow
increas remyelin novarti nyse nv gilenya fingolimod target receptor subtyp although
thought interact subtyp drug first oral administ drug approv
treatment rrm market gilenya well establish novarti lose patent protect
loss patent protect number gener product expect enter market compet market
share drug target receptor potenti better specif ozanimod
siponimod ponesimod
drug target
develop prodrug monomethyl fumar
mmf drug deliv oral effici convert mmf bodi similarli tecfidera
approv drug treatment ms prodrug convert dimethyl fumar bodi alkerm
recent launch two pivot phase studi investig treatment patient
rrm result primari endpoint expect earli
geneuro lead candid monoclon antibodi envelop protein multipl
sclerosi associ retroviru msrv-env human endogen retrovir herv genet element
silent healthi peopl ubiquit express multipl sclerosi ms lesion msrv-env shown
activ toll-lik receptor pathway compon innat immun system propos
causal trigger neuroinflamm neurodegener seen ms compani current conduct
phase iib trial expect report data late
coheru bioscienc develop modul peroxisom
proliferator-activ receptor gamma pparg importantli abl cross blood brain barrier act
central nervou system bring anti-inflammatori effect phase iib studi number new
lesion significantli reduc mg treat group reduct compar placebo
opicinumab shire shpg develop
opicinumab antibodi drug target protein protein shown inhibit
differenti oligodendrocyt cell subsequ neuron myelin anim model antagon
led increas remyelin shire complet two phase ii trial efficaci
garri et al receptor signal cell traffick beyond immunolog
safeti drug treatment ms shire launch phase iib studi studi opicinumab
add-on therapi rrm patient studi current recruit
pregabalin er extended-releas formul lyrica
mapi pharma also develop extend releas formul pregabalin activ ingredi pfizer
nyse lyrica mapi co-develop product jiangsu nhwa pharmaceut co ltd
base china lyrica wide prescrib drug treatment neuropath pain lyrica gener
approxim billion world-wide revenu us annual cost pain includ direct medic cost
indirect cost societi estim billion underscor need effect
mean pain lyrica go off-pat allow entri gener market mapi
pharma partnership jiangsu nhwa pharmaceut co ltd complet pharmacokinet studi china
confirm safeti efficaci extended-releas formul compani plan run second
pharmacokinet studi eventu pursu approv product regulatori pathway use
lyrica refer drug
mechan action pregabalin acid molecul structur
relat g-aminobutyr acid gaba major inhibitori neurotransmitt pregabalin known
anticonvuls analges effect research believ effect mediat bind
subunit presynapt voltage-g calcium channel illustr figur pregabalin act antagonist
voltage-g calcium channel decreas influx calcium presynapt neuron calcium
need releas neurotransmitt axon termin decreas presynapt calcium mean
less neurotransmitt releas subsequ less impact postsynapt fire
figur synapt mechan action pregabalin
gaskin richard econom cost pain unit state pain
neuropath pain defin pain aris due lesion diseas caus damag somatosensori
neuropath pain caus wide varieti injuri diseas manag chronic pain
often consid challeng medic due subject natur pain heterogen
underli caus difficult treatment effect eas symptom neuropath pain patient tend
experi higher averag pain score lower qualiti life measur overal health-rel qualiti life
adjust pain score requir medic report less relief symptom follow treatment compar
nonneuropath pain patient high unmet need among neuropath patient evid
caus pathogenesi neuropath pain aris damag somatosensori nervou damag
differenti base locat associ symptom individu undergo damag
sensori mix peripher nerv damag central somatosensori pathway individu experi
area sensori deficit region normal innerv damag nerv pathway figur provid
overview differ form neuropath pain respect caus nerv damag eventu lead
develop neuropath
figur overview differ type neuropath pain respect caus
type neuropath pain
caus nerv damag
chronic high blood glucos level neurovascular damag
featur diabet
hiv viru anti-hiv medic
neurotox effect chemotherapi treatment
rewir nerv follow limb amput signal pain
autoimmun disord immun system attack
cerebrovascular insult due stroke
treed et al neuropath pain redefinit grade system clinic research purpos neurolog
baron binder wasner neuropath pain diagnosi pathophysiolog mechan treatment
baron binder wasner neuropath pain diagnosi pathophysiolog mechan treatment
connor dworkin treatment neuropath pain overview recent guidelin american jouranl
ectop nerv activ sensat on-going spontan pain shoot pain without extern stimuli
indic ectop impuls gener within pain process follow damag nerv
spontan activ damag undamag unmyelin thinli myelin affer fiber lower
activ threshold fiber associ higher level mrna voltage-g sodium channel
sodium channel lower activ threshold ectop activ may continu occur
nerv damag may also caus chang voltage-g potassium channel contribut neuron
central sensit follow ectop activ primari nocicept affer fiber sensit central
neuron occur without damag peripher affer fiber continu activ
may bring releas tachykinin neurotransmitt glutam calcitonin gene-rel peptid
cgrp gaba dorsal horn spinal tachykinin neurotransmitt lead
postsynapt chang second-ord nocicept neuron nmda ampa receptor phosphoryl
recruit plasma postsynapt chang turn lead hyperexcit low-
threshold mechanosensit ab ad affer fiber activ second-ord nocicept fiber disinhibit may
also occur combin sensit central nervou system disinhibit inhibitori control
mechan lost increas neuron excit occur
effect inflamm inflamm follow nerv damag lead activ macrophag recruit
macrophag nerv dorsal root ganglion macrophag recruit may contribut pain hypersensit
macrophag releas pro-inflammatori cytokin tumor necrosi factor activ microglia
also contribut pain releas immunomodul maintain durat neuropath pain
chemic produc inflamm noradrenalin bradykinin histamin prostaglandin potassium
cytokin norepinephrin serotonin neuropeptid lead peripher sensit decreas
threshold activ lead neuron hyperexcit peripher sensit occur damag
undamag fiber induc chang express voltage-g sodium channel neuron membran
prolong hyperexcit
symptom diagnosi chronic pain fall three categori nocicept pain due tissu diseas damag
neuropath pain caus somatosensori system diseas damag combin neuropath
nocicept pain call mix neuropath pain clinic associ spontan on-going shoot
pain augment evok pain respons noxiou non-noxi neuropath pain also
commonli report involv burn crawl tingl electr common type
peripher neuropath pain follow pain diabet neuropathi postherpet neuralgia complex region pain
woolf mannion neuropath pain aetiolog symptom mechan manag lancet
woolf mannion neuropath pain aetiolog symptom mechan manag lancet
pasero pathophysiolog neuropath pain pain manag nurs
pasero pathophysiolog neuropath pain pain manag nurs
baron binder wasner neuropath pain diagnosi pathophysiolog mechan treatment
baron binder wasner neuropath pain diagnosi pathophysiolog mechan treatment
baron binder wasner neuropath pain diagnosi pathophysiolog mechan treatment
relat cancer-rel relat infecti diseas lyme
treatment commonli pharmacolog treatment use address neuropath pain common drug
serotonin norepinephrin reuptak inhibitor calcium channel ligand opioid analges lidocain figur
provid overview commonli prescrib drug neuropath pain
figur overview current neuropath pain treatment
mode action
inhibit serotonin
reuptak block sodium
inhibit serotonin
norepinephrin
inhibit serotonin
norepinephrin
decreas releas
norepinephrin
decreas releas
norepinephrin
block sodium channel
daili twice
time daili
everi hr
inhibit
norepinephrin
twice
long-act drug
note phn postherpet neuropathi central pain spinal cord injuri
giambon public meet patient-focus drug develop neuropath pain associ peripher
neuropathi drug administr present june
import note wide varieti medic treatment neuropath pain efficaci
reduc pain remain fairli low due overal low efficaci treatment pain reduct least
consid clinic addit low efficaci treatment inconveni associ
treatment may decreas complianc lyrica administ time per day depend appropri dosag
individu respect condit commonli use treatment also often requir multipl daili
dose inconveni mani patient one studi found patient treat gabapentin
noncompli treatment non-compliance defin take less schedul
treatment complianc may contribut overal low efficaci drug treatment neuropath pain
press need treatment offer conveni administr thusli encourag treatment complianc
epidemiolog neuropath pain fall within wider chronic pain indic shown figur
figur classif pain
roughli million peopl us chronic pain preval neuropath pain estim
us translat total roughli million howev estim million
individu us level peripher neuropath pain categor base
underli diseas induc neuropath pain common form includ postherpet neuralgia phn
baron binder wasner neuropath pain diagnosi pathophysiolog mechan treatment
giannopoulo et al patient complianc neuropath pain treatment pain
melnikova analyst couch pain market natur review drug discoveri
advanc manag neuropath pain phi rehabil clin
nation institut
trigemin neuralgia tn peripher diabet neuropathi dpn diabet peripher neuropathi
common form roughli cancer patient also develop neuropath pain pain may either aris due
diseas effect cancer therapi treatment chemotherapi exampl
patient undergo chemotherapi suffer chemotherapy-induc neuropath pain
neuropath pain found common women men common older
individu diseas age-of-onset variabl often base underli pain-caus diseas diseas
peak year treat np estim patient np
major patient current treat nsaid aspirin
market size center diseas control prevent estim unit state total trillion
chronic pain manag signific contributor overal healthcar cost us pain
manag includ direct medic cost indirect cost societi estim
estim may conserv account individu age nurs
home resid militari personnel incarcer individu compar annual cost associ heart
diseas cancer diabet estim respect billion billion
direct medic cost associ np tend depend underli diseas exampl one studi
found annual cost associ post-herpet neuralgia anoth studi report annual
cost associ moder pain diabet peripher neuropathi one studi
look gener neuropath pain estim direct annual healthcar cost compar
control subject signific loss product associ neuropath pain
addit indirect cost relat diseas one studi report individu np
employ miss work and/or reduc product level
price market share analysi figur provid overview current fda-approv treatment
neuropath pain patent number brand drug expir gener expect erod larg market
share drug like lyrica cymbalta lyrica current market leader neuropath pain indic
total billion us sale billion world-wide sale drug go patent
cymbalta next most-wid prescrib drug neuropath pain gener million world-wide sale
dieleman et al incid rate treatment neuropath pain condit gener popul
mccarberg billington consequ neuropath pain quality-of-lif issu associ cost american
journal manag
gaskin richard econom cost pain unit state pain
gaskin richard econom cost pain unit state pain
dworkin et al impact postherpet neuralgia pain diabet peripher neuropathi health care cost
gore et al burden ill pain diabet peripher neuropathi patient perspect pain
figur overview approv treatment neuropath pain
europ
figur provid annual price approv treatment neuropath pain mapi pregabalin er product
extend releas formul pfizer lyrica lyrica goe off-pat number gener version
lyrica soon enter market drive annual price pregabalin-bas drug mapi pharma
extend releas reformul lyrica like price premium compar gener
figur annual price approv neuropath pain treatment
price depend dose
partnership jiangsu nhwa pharmaceut co ltd mapi complet pharmacokinet studi china
evalu extended-releas pregabalin product studi evalu er formul consist two
compon first compon provid releas drug period second compon
provid drug releas period detail studi limit mapi plan run second
pharmacokinet studi develop pregabalin er product
competit landscap neuropath pain treatment
improv formul market leader lyrica pregabalin er extend releas form pfizer lyrica
lyrica histor led neuropath pain market sale gener billion us lyrica
administ time per day depend appropri dosag individu respect
condit pregabalin er compar administ daili increas conveni drug
administr like improv patient complianc treatment mapi product improv
formul lyrica may well-posit captur substanti market share lyrica goe off-pat
addit may creat strong financi incent acquir world-wide right mapi
pregabalin formul order preserv revenu stream one studi found patient treat
gabapentin noncompli treatment non-compliance defin take less schedul
treatment complianc lead difficulti manag chronic pain pregabalin er may allow
patient gain greatest benefit treatment
econom burden chronic pain opioid treatment pain chronic pain signific
contributor total healthcar cost unit state estim annual cost associ direct
indirect aspect chronic pain believ billion greater cost
associ cancer heart diseas diabet individu neuropath pain spend approxim three-fold
unaffect individu annual healthcar cost addit studi found individu
neuropath pain employ miss work decreas product pain symptom
one studi worker experienc headach averag loss product time hour per week
worker back pain arthriti averag loss product time hour per week common pain
condit associ averag loss product time hour per
addit burden pain place individu societi use opioid treatment pain
contribut overal burden associ condit mani individu suffer chronic pain
eventu prescrib opioid manag pain opioid product abl provid pain relief
also addict prone abus use excess amount especi individu build
toler opioid caus respiratori central nervou system depress may eventu lead
death recent year increasingli potent synthet opioid drug fentanyl becom avail
result death due opioid use grown exponenti death due synthet opioid specif risen
past three year drug overdos death total roughli econom burden associ
giannopoulo et al patient complianc neuropath pain treatment pain
stewart et lost product time cost due common pain condit us workforc jama network
opioid use abus estim billion report council econom
effect safe treatment pain urgent need
drug develop np
mani drug develop treatment neuropath pain order drug receiv broad
label neuropath pain fda stipul potenti treatment must evalu three trial three
differ neuropath pain indic figur provid overview late-stag treatment current
develop neuropath pain
figur late-stag treatment develop neuropath pain
council econom advis underestim opioid crisi execut offic presid
risperidon lai once-monthli formul risperd consta
develop gener long-act inject formul atyp antipsychot risperidon
treatment schizophrenia risperidon activ ingredi johnson johnson risperd
approv fda johnson johnson later develop version risperd requir twice-monthli
dose oppos daili dose second version drug risperd consta approv fda
despit improv dose conveni treatment complianc among patient schizophrenia
remain low recent studi found individu schizophrenia respond medic
adher mapi risperidon lai formul allow once-monthli dose could reduc
treatment burden improv complianc number studi found depot formul
antipsychot well-toler efficaci associ higher complianc compar oral drug
complianc consid critic factor overal treatment outcom gener treatment
protocol conveni complianc rate higher current plan bioequival trial
risperidon lai follow trial plan pursu regulatori pathway use risperd
consta refer drug
mechan action risperidon atyp antipsychot block serotonin dopamin
adrenalin histamin receptor drug rel low bind affin acetylcholin muscarin
-adrenerg receptor bind affin common among class atyp antipsychot
risperidon thought exert antipsychot activ modul dopaminerg serotonerg pathway
howev becdaus pathogenesi schizophrenia well understood exact manner
neurotransmitt system affect schizophrenia well understood
safeti profil risperidon first approv oral atyp antipsychot risperd use treat patient
schizophrenia drug use extens patient popul sinc approv lai formul
risperidon risperd consta approv thu safeti profil risperidon schizophrenia
patient popul well understood
schizophrenia debilit mental ill typic present adolesc earli adulthood
associ heterogen spectrum psychiatr symptom includ hallucin disorgan think
delus paranoia cognit pathogenesi schizophrenia well understood
although mani genet environment development risk factor disord identifi
cure schizophrenia affect individu need lifelong therapi manag symptom prevent psychot
el-mallakh findlay strategi improv medic adher patient schizophrenia role
kane et al long-act inject risperidon efficaci first long-act atyp antipsychot psychiatri
lakhan se vieira schizophrenia pathophysiolog closer complet model annal gener
caus pathogenesi exact caus pathogenesi schizophrenia well-understood diseas
thought involv interplay genet environment development factor lead alter brain
structur inappropri neural signal schizophrenia known run famili famili histori
diseas singl signific risk howev singl gene respons
develop schizophrenia mani genet allel confer increas risk develop schizophrenia
although role gene diseas manifest understood present studi
found ident twin individu schizophrenia greater chanc develop
diseas immedi famili member diseas confer risk develop schizophrenia
rang environment factor contribut diseas manifest individu heighten
risk schizophrenia environment factor includ
complic pregnanc prenat viral infect
traumat highli stress life situat
wide rang chang identifi postmortem brain individu schizophrenia
certain brain area investig found reduct brain volum increas pyramid neuron densiti
atyp dendrit tree reduc number axon synaps myelin alter chang ventricl size
anatom physiolog differ brain healthi individu report
gliosi brain schizophren patient indic diseas result degen
inflammatori broad chang found brain support neurodevelopment etiolog
schizophrenia lot diseas still unknown
symptom diagnosi individu schizophrenia present heterogen mix symptom
classifi either posit neg posit symptom auditori hallucin delus featur
gener affect healthi individu neg symptom deficit normal emot trait
usual present social withdraw flatten affect poor figur highlight
common posit neg symptom associ schizophrenia individu schizophrenia also
cognit difficulti manifest troubl process inform complet task understand
environ rememb simpl thing
mortensen pb et al effect famili histori place season birth risk schizophrenia new england
journal medicin
pearlson gd folley bs schizophrenia psychiatr genet darwinian psychiatri evolutionari
selemon ld et al abnorm high neuron densiti schizophren cortex morphometr analysi
prefront area occipit area archiv gener psychiatri
selemon ld et al region specif neuropatholog substrat schizophrenia morphometr analysi
broca area area archiv gener psychiatri
mki et al predictor schizophreniaa review british medic bulletin
figur common posit neg symptom associ schizophrenia
lack emot
inabl experi pleasur
lack interest relationship
lack motiv
definit test schizophrenia diagnosi made interview patient
well friend famili diagnosi schizophrenia typic reach posit neg symptom
present month longer signific impair patient qualiti life
symptom readili explain condit drug use diagnosi symptom must includ
least two follow delus hallucin disorgan speech cataton behavior neg symptom
identifi diseas earli possibl greatli improv patient chanc success manag ill
reduc likelihood hospit admiss individu take long decad reach
diagnosi schizophrenia
treatment first-lin therapi schizophrenia patient drug class known atyp second-
gener antipsychot first drug within class approv fda clozaril clozapin
follow johnson johnson risperd risperidon eli lilli zyprexa olanzapin
drug replac older gener antipsychot caus sever motor side effect due interact
extrapyramid motor system brain figur highlight approv short-act drug schizophrenia
also approv long-act inject lai formul drug shown figur
figur drug approv us treatment schizophrenia
patient diagnos schizophrenia typic start atyp antipsychot select base
past experi physician expect advers event profil current treatment guidelin britain
nation institut excel american psychiatr associ
schizophrenia patient outcom research port recommend lai primarili patient recurr
relaps link poor adher howev grow bodi research indic lai improv patient
complianc may optim first-lin therapi broader rang schizophrenia patient figur
highlight six lai current market current respect us market share johnson
johnson nyse risperd consta invega sustenna invega trinza nyse zyprexa relprevv
otsuka/lundbeck over-the-counter otsky/ over-the-counter hluyi abilifi maintena
aristada johnson johnson current domin lai market roughli share
usd million
note indic combin sale zyprexa zyprexa relprevv product
risperd consta risperidon johnson johnson risperd consta long-act inject formul
drug risperidon second-gener atyp antipsychot use treat schizophrenia risperd consta
first second-gener atyp antipsychot reach market receiv fda approv
risperidon dopamin antagonist addit antagonist activ serotonerg adrenerg histaminerg
receptor risperd consta administ via intramuscular inject everi two week provid slow releas
inject site risperd consta take week reach therapeut level peak serum level
attain day inject necessit use oral risperidon least week start lai
invega sustenna invega trinza paliperidon palmit johnson johnson invega sustenna long-
act inject formul paliperidon atyp antipsychot first approv
treatment schizophrenia paliperidon primari activ metabolit risperidon compar antagonist
activ dopamin serotonin adrenalin histamin signal pathway invega sustenna deliv via once-
monthli intramuscular inject two initi load dose space one week apart fda approv
invega trinza three-month inject use activ ingredi invega sustenna
zyprexa relprevv olanzapin pamoat zyprexa relprevv long-act inject formul
atyp antipsychot olanzapin product broad antagonist activ serotoninerg dopaminerg
adrenerg histaminerg cholinerg muscarin receptor administ everi week via intramuscular
inject requir oral supplement load dose product contain box warn
fda due risk develop post-inject delirium sedat syndrom pdss character
sedat confus loss conscious within sever hour inject fda requir rem
wherebi patient requir receiv zyprexa relprevv inject rems-certifi health care facil
continu monitor facil least hour follow inject accompani home
facil fda investig two death patient take zyprexa relprevv result studi
inconclus fda make chang prescript recommend drug
abilifi maintena aripiprazol otsuka/lundbeck abilifi maintena long-act inject formul
atyp antipsychot aripiprazol approv fda februari aripiprazol partial
dopamin serotonin agonist differ mechan action atyp antipsychot abilifi
maintena deliv monthli intramuscular inject necessit consecut day oral supplement
aripiprazol sinc drug take day reach steady-st concentr brain product
suppli lyophil powder store room temperatur need reconstitut steril water prepar
inject solut
aristada aripiprazol lauroxil aristada long-act inject formul atyp
antipsychot aripiprazol approv fda aristada extended-releas formul abilifi
like abilifi aristada deliv via intramuscular inject monthli six-week two-month
formul aristada treatment requir day oral aripiprazol first inject order
drug reach stead-stat concentr brain drug suppli pre-fil syring requir
epidemiolog accord nation institut mental health schizophrenia affect roughli peopl
world-wide us popul year old diseas typic manifest earlier men
women first episod occur mean age year respect age men
women schizophrenia manifest diseas figur highlight address schizophrenia
patient popul us approxim million peopl schizophrenia new
case diagnos year although healthcar expert predict addit go undiagnos long-act
inject lai antipsychot use roughli market amount individu
us popul
market size although preval schizophrenia rel low diseas exact substanti burden
affect individu famili us overal econom burden treat schizophrenia
billion annual direct indirect cost schizophrenia account roughli total healthcar
expenditur make one expens adult diseas patient schizophrenia
usual requir form daili live support rest live addit patient relaps larg cost
driver treatment schizophrenia due high cost inpati servic rehospit cost
relat antipsychot non-adher amount nearli roughli non-compli patient
hospit cours year commonli cite driver relaps adher use
lai drug class shown reduc rate non-compliance could reduc occurr patient
relaps addit risperidon lai provid conveni dose could encourag lai use
simplifi process reiniti therapi relaps
us market antipsychot domin sever blockbust drug includ seroquel quetiapin abilifi
aripiprazol risperd risperidon zyprexa olanzapin togeth make roughli market
drug come patent face gener competit attempt avoid competit
compani launch extended-releas formul drug provid greater conveni
within us sale lai amount billion worth note sale number encompass
use lai across sever psychiatr condit indic use lai expect grow
substanti long-act treatment becom recogn suitabl first-lin therapi broad rang
patient schizophrenia sinc risperidon lai design improv patient adher conveni
therefor offer greater conveni treatment compar current market leader may abl
gain substanti share lai market
competit landscap schizophrenia treatment
poor adher therapi major driver patient relaps consist cost driver treatment
schizophrenia due high cost inpati servic roughli hospit visit case
schizophrenia result readmiss within partial adher fulli non-compli patient mean
hospit stay durat day high cost associ relaps creat strong
alber lj et al iloperidon new benzisoxazol atyp antipsychot drug novel enough impact
bernardo et al cost-effect analysi schizophrenia relaps prevent econom evalu
ziprasidone-extended-use-in-schizophrenia studi spain clinic drug investig
bartel sj et al medicar medicaid cost schizophrenia patient age cohort compar cost
depress dementia medic ill patient american journal geriatr psychiatri
sun sx et al review analysi hospit cost associ antipsychot nonadher treatment
schizophrenia unit state current medic research opinion
sun sx et al review analysi hospit cost associ antipsychot nonadher treatment
schizophrenia unit state current medic research opinion
olivar jm et al definit driver relaps patient schizophrenia systemat literatur review
annal gener psychiatri
elixhaus steiner readmiss hospit diagnosi healthcar util project
ascher-svanum et al medic adher level differenti use mental-health servic treatment
econom incent treatment better promot treatment complianc lai use shown reduc
hospit rate care
also intend leverag expertis formul long-act product develop buspiron er
regulatori pathway buspiron er extend releas formul bristol-my squibb
nyse buspar daily-administ oral antipsychot use treatment anxieti buspar gener
approxim million sale also develop gener drug candid anda
regulatori pathway figur provid overview candid
figur overview anda pathway compound
focus develop finish dose form fdf gener version brand drug
lose patent exclus specif develop complex api
tend higher barrier entri market like lower number gener competitor
figur display mapi patent portfolio contain patent famili complex api formul
peng et al declin hospit risk health care cost initi depot antipsychot
treatment schizophrenia clinicoeconom outcom research
offord et al healthcar resourc usag schizophrenia patient initi long-act inject antipsychot vs
oral journal medic econom
formul patent us patent
grant titl depot system compris glatiram
us patent number ep patent
grant titl process prepar darunavir
darunavir intermedi
us patent number titl polymorph
darunavir ep patent titl
dimethylsulfoxid solvat darunavir
compound process prepar
us patent number grant titl co-cryst
us patent number grant titl process
intermedi prepar abirateron acet
us patent number titl polymorph
compound process prepar lurasidon
us patent number grant ep patent
decis grant titl process
prepar deferasirox deferasirox polymorph
us patent number il patent number
grant titl intermedi compound process
prepar tapentadol relat compound
us patent number grant titl process
prepar alogliptin
pentapolym treatment autoimmun diseas
ehud marom one founder serv chief execut offic chairman board
director sinc incept januari mr marom year manag oper experi
life scienc industri prior found mr marom serv variou senior posit multi-national
pharmaceut compani includ vice presid two divis teva pharmaceut industri ltd
launch copaxon current sale billion per year head copaxon
global oper team head global oper teva pharmaceut industri ltd chemic divis
mr marom serv presid peptor ltd led pharmaceut develop
innov diabet product diapep mr marom serv chief execut offic gamida-
cell ltd stem cell develop compani mr marom serv chief execut offic
makhteshim compani annual sale billion world leader brand off-pat crop protect
solut later becam makhteshim-agan ltd sinc acquir china nation
agrochem corpor subsidiari china nation chemic corpor mr marom serv vice
presid suppli makhteshim-agan industri ltd current serv also chairman
pharma help guid product treatment earli diagnos parkinson diseas
success phase iib pivot trial expect regist via regulatori pathway mr maron
serv well chief execut offic chairman stem cell medicin ltd ehud sc chemic
engin honor technion israel
danon serv execut vice presid sinc octob accumul five year end
mr danon serv presid later chief execut offic biocancel therapeut inc tase
bicl clinic stage anti-canc drug develop compani also previous serv chief execut offic
atox ltd clinic stage drug develop compani focus treatment sever infect serv
compani chairman board director novemb previous manag
intern project teva pharmaceut ltd includ develop copaxon solut
pre-fil syring current sale approxim billion per year chief
execut offic epigenesi ltd cell therapi develop compani mr danon hold
market bar ilan univers israel sc industri engin manag tel
nir bernstein serv vice presid financ sinc septemb mr bernstein serv chief
financi offic novemb septemb octob octob mr bernstein
serv vice presid account control ampal-american israel corp inc public compani
ampl acquir interest busi locat oper israel august
septemb mr bernstein work senior manag pricewaterhousecoop intern account
firm mr bernstein hold manag account colleg manag sc
physic hebrew univers jerusalem israel
shai rubnov serv vice presid research develop sinc dr
rubnov serv head chemistri manufactur control qualiti assur regulatori affair therapix
bioscienc ltd formerli nasvax ltd isra drug develop compani dr rubnov
serv director chemistri manufactur control develogen ag german-isra biotechnolog
compani gain extens experi investig new drug develop medicin chemistri
dr rubnov hold phd medicin chemistri bpharm hebrew univers jerusalem israel dr
rubnov complet post-doctor train french nation center scientif research pari
mogl serv vice presid corpor develop sinc june mr mogl year
execut experi life scienc chemic industri mr mogl serv sever
capac includ compani secretari investor relat director head suppli chain makhteshim
ltd respons sale plan inventori manag valu
billion prior makhteshim agan ltd mr mogl serv busi develop manag digit
video divis nice system ltd economist isra ministri financ mr mogl
honor econom major financ account hebrew univers
safi landskron serv vice presid busi develop regulatori affair sinc octob
ms landskron experi develop new busi proven track record intern regulatori
affair ms landskron serv head procur divis meuhedet sick
fund ms landskron serv busi develop consult vice presid posit
neopharm ltd ms landskron current serv director therapix bioscienc ltd tase trpx ms
landskron previous serv research develop project manag later vice presid busi
develop regulatori affair dexcel pharma ltd ms landskron hold mba bradford univers
uk bpharm hebrew univers jerusalem israel
laura popper serv medic director sinc septemb dr popper bring year
experi pharma prior join mapi dr popper serv senior
posit world lead pharmaceut compani cover vast arena therapeut area
recent serv medic affair manag astella tyo follow four year medic manag
sanofi previous medic advisor pharmacovigil countri head bayer dr popper start
career pharmaceut industri clinic director foamix fomx dr popper hold
univers bueno air post-doctor neurobiolog weizmann institut
scienc dr popper pediatrician train complet internship medicin resid pediatr
serv teach assist pharmacolog biochemistri chair univers bueno air
head api develop
david leonov serv head api develop sinc februari june februari
dr leonov employ makhteshim agan industri ltd serv chief scientist charg
compani gener innov product serv leader compani research develop
expans india prior dr leonov employ teva pharmaceut industri ltd year
last posit serv head global research develop israel india unit state
hungari dr leonov earn phd chemistri weizmann institut scienc rehovot
continu post-doctor train univers chicago
head formul
yoram sela serv head formul sinc incorpor januari join board
director upon close offer dr sela year experi develop formul
drug deliveri system previous dr sela found period nine year manag drug-deliveri unit
teva pharmaceut industri ltd addit dr sela co-found serv director karma-pharm
ltd vice presid research develop lycor ltd dr sela serv vice
presid research develop nesher solut israel decemb dr sela found gc group
ltd serv chief execut offic dr sela earn phd sc chemistri sc agricultur
hebrew univers jerusalem israel
risk invest
consid invest mapi pharma high-risk invest mapi development stage compani
histori take treatment market current fda ema approv product portfolio
compani product develop may fail clinic trial fail approv fda regulatori
agenc furthermor earli indic efficaci necessarili translat posit late-stag result
compani mapi may unabl obtain suffici capit fund plan develop program regulatori
approv market sell drug guarante drug penetr market sale may meet
expect investor
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
